載入...
Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease
BACKGROUND: The optimal chemotherapy regimen for non-small-cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) remains unknown. Therefore, in this study, we investigated the real-world efficacy and safety of carboplatin (CBDCA) plus nab-paclitaxel (nab-PTX) as a first-line regimen...
Na minha lista:
| 發表在: | Cancer Manag Res |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove Medical Press
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6298387/ https://ncbi.nlm.nih.gov/pubmed/30588105 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S189556 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|